United States: Trying To Infuse® Common Sense Into Parallel Claims And Off-Label Promotion

Last Updated: May 12 2015
Article by Michael A. Walsh

Truthful Scientific Information: A Compelling Health Imperative

Why is it that the Food and Drug Administration (FDA) is suggesting it will conduct a meeting in the summer of 2015? Perhaps the FDA has had its fill after reaping more than $12 billion in penalties. More likely the landmark decision in US v. Caronia, 703 F.3d 149 (2d Cir. 2012) was the watershed decision that everyone, except the FDA, said it was. Moreover, pressure has been mounting as the House Commerce Committee is considering the "21st Century Cures Act" that potentially includes a provision on off-label communications; the Medical Information Working Group's (i.e. a coalition of big pharma) 2011 and 2013 petitions still lurk; and a myriad of litigation is challenging the current scheme of regulation. While it is unclear what form any new rule may take, it has been clear for more than a decade that the current regime offends the US Constitution on many fronts, foments litigation and—by hindering the flow of truthful scientific and medical information—fails to protect the public.

As the brouhaha continues, courts are contorting themselves to untangle the spaghetti bowl of cases applying federal preemption to state law parallel claims for off-label promotion. For example, in Caplinger v. Medtronic, 2015 U.S. App. LEXIS 6630 (10th Cir. April 21, 2015), the Tenth Circuit observed in a 2-1 decision that courts need not delve into the Food Drug and Cosmetic Act (FDCA) or FDA regulations to craft a cognizable claim regarding Medtronic's Infuse® off-label promotion that the plaintiff had failed to plead. While affirming the lower court's dismissal of the complaint on preemption grounds, the court wrestled with the murky morass of Supreme Court "parallel claim" preemption precedent and the question of state-tort claim survival under the primacy of the supremacy clause stating:

All the same the Lohr majority adopted a test that leaves it to lower courts to try to resolve whether a state duty is "literally different" but "narrower" (and thus permissible) or "too different" and "broader" (and thus impermissible). Lower courts have struggled ever since when it comes to trying to decide whether particular state claims do or don't "parallel" putative federal counterparts. Id. at 8

The Court went on to suggest that perhaps there is a need for a bit of Supreme Court clarity in this arena saying:

How are we supposed to apply all these competing instructions? It's "no easy task."... One can't help but wonder if perhaps some of those rules warrant revisiting and reconciliation... It's no wonder that the difficulty of crafting a complaint sufficient to satisfy all these demands has been compared to the task of navigating between Scylla and Charybdis. Id at *12-13 (citations omitted).

Further musing on the plaintiff Caplinger's frustration and offering a prayer of hope but no guidance, the court asserted:

That's not to say another plaintiff won't ever be able to succeed where Ms. Caplinger has failed. For example, we don't question the possibility that buried somewhere in the heap of federal law parallel provisions exist to save claims like Ms. Caplinger's. After all, the FDA's medical device regulations alone cover 592 pages of eight-point type and the Supreme Court has suggested that in searching for a parallel federal duty a plaintiff may scour them all as well as the statute itself. And lurking in there somewhere might be some answer to the apparent conundrum of how a plaintiff might use state law to require more label warnings that federal law seems to prohibit. But despite the challenge of Medtronic's motion to dismiss, Ms. Caplinger has never -- in all her voluminous briefs in the district court or this one -- identified any legally viable federal requirement that might parallel and thus permit her claims. Neither are the courts under an obligation to perform that work for her, searching out theories and authorities she has not presented for herself. Indeed, we are especially hesitant to try that here, where Ms. Caplinger has been ably represented by counsel and the effort to supplement their efforts would require us to venture into a field in which so many others who've come before have struggled to find their way and there exists so much risk of going astray. Id. at *18.

The Caplinger case is not notable merely because plaintiff failed to frame a cognizable cause of action. More troubling is the Court's failure to recognize the trend adopted by plaintiffs to rely on an "off-label promotion" claim as a pretext to circumvent preemption and there the Court observed:

In not a single one of its many and involved encounters with the MDA has the Supreme Court so much as hinted at this [off-label promotion] alternative path around preemption. But Ms. Caplinger says its past obscurity shouldn't stop us from recognizing it now. Id. at *23

Off-Label Versus New Drug

The Court got a bit undone sifting through the FDCA and FDA's regulations and "guidance." It is undoubtedly true that the Supreme Court has yet to recognize if, how, when, why and under what precise analysis the Court will recognize a tort claim for conduct deemed "promotion" of an unapproved new drug or device .

The Tenth Circuit's reasoning becomes murky when it focuses on Congress' limiting the FDA's power to restrict physicians from "using" a product in a manner that is not in the approved product labeling. 21 USC §396. Here, the Court observed that Congress shifted the risk to patients and physicians. What the Court ignored and Plaintiff failed to raise, is that the FDCA goes on to state:

This section shall not limit any existing authority of the Secretary to establish and enforce restrictions on the sale or distribution, or in the labeling, of a device that are part of a determination of substantial equivalence, established as a condition of approval, or promulgated through regulations....

Further, this section shall not change any existing prohibition on the promotion of unapproved uses of legally marketed devices." Id.

Who Is Doing What?

Conflating a physician's off-label use in the practice of medicine and a manufacturer's marketing of an unapproved device, the Court observed:

It's easy to imagine, too, why Congress adopted a preemption provision [21 USC §360k(a)] that doesn't distinguish between on-and off-label uses. Any additional state duties on top of those imposed by federal law, even if nominally limited to off-label uses, might check innovation, postpone access to life-saving devices, and impose barriers to entry without sufficient offsetting safety gains. Caplinger at *29-30.

The Court is correct suggesting any rule should not stifle innovation or limit life-saving therapy, but the Court was correct perhaps for the wrong reason. The preemption provided under §360k does not reference off-label to protect innovation but exists because clearance is premised solely on approved uses. On this point, the dissenting opinion in Caplinger would have allowed the claims to proceed.

The path forward is less clear than the Tenth Circuit supposed. The FDA views off-label promotional conduct as evidence of intent to market an unapproved new device. While §396 prohibits FDA from exerting authority over physicians "using" a device off label, the prohibition does not expressly extend to "promotion" by manufacturers. What the Court and the plaintiff in Caplinger did not recognize is that "use" falls under the umbrella of medical judgment, whereas promotion of new device falls under the realm of FDA clearance or approval.

What does this mean in the context of preemption? When marketing and promotional conduct are not tethered to FDA authorized procedures for the dissemination of scientific or medical information on new uses, manufacturers risk FDA enforcement. In addition, plaintiffs may have viable tort claims against manufacturers marketing a device without FDA clearance on the grounds that the conduct violates both the FDCA and relevant state law.

The plaintiff's inability to plead a coherent parallel claim for promoting a new use saved the defendant in Caplinger. The FDCA, as well as the Supreme Court opinions allowing a state-law tort claim where they "parallel" the FDCA remain imprecise. Until and unless the Supreme Court or Congress comprehensively review the underlying policy considerations surrounding off-label use for approved products, the "conundrum" noted by the Tenth Circuit in Caplinger will continue.

A health and public policy imperative that physicians should have more information concerning products, particularly those they use for indications that are not FDA approved or cleared underlies this purported tort of off-label promotion. While preemption has provided ample fodder for constitutional wrangling over permissible and impermissible tort claims, a greater hurdle in the saga of preemption lies ahead. Whether the emerging Supreme Court precedent on deference, due process and the First Amendment will provide the remedy for industry or create a far greater dilemma is a pressing question.

Conclusion:

The manufacturer in Caplinger obtained a good result, but the Tenth Circuit's 2-1 opinion does not put the preemption issue to rest, but instead portends more litigation. The controversy over off-label uses for approved products will continue until Congress mandates change or the FDA revises its approach. In the interim, manufacturers should tether the conduct of their marketers to recognized avenues of dissemination of medical and scientific information. Marketers' who deviate from those paths will create an Achilles' heel manufacturers will be forced to defend.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Michael A. Walsh
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Emails

From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.